Hence, we conducted a meta-analysis of the published literatures to explore the association between the persistence of T790M and the clinical benefits of Osimertinib in NSCLC patients with baseline EGFR T790M mutation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.